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Matrix-metalloproteinase-13 (MMP-13) has been shown to be an important protease in inﬂammatory and neoplastic conditions
of the skeletal system. In particular, the stromal cells of giant cell tumor of bone (GCT) express very high levels of MMP-13 in
response to the cytokine-rich environment of the tumor. We have previously shown that MMP-13 expression in these cells is
regulated, at least in part, by the RUNX2 transcription factor. In the current study, we identify the expression of the c-Fos and
c-Jun elements of the AP-1 transcription factor in these cells by protein screening assays and real-time PCR. We then used siRNA
gene knockdown to determine that these elements, in particular c-Jun, are upstream regulators of MMP-13 expression and activity
in GCT stromal cells. We conclude that there was no synergy found between RUNX2 and AP-1 in the regulation of the MMP13
expression and that these transcription factors may be independently regulated in these cells.
1.Introduction
Bone resorption involves dissolution of the nonorganic
component of bone, speciﬁcally hydroxyapatite, followed
by degradation of the collagenous component composed
mostly of type-I collagen [1]. Although osteoclasts and their
ability to create a highly acidic environment are considered
necessary for the degradation of hydroxyapatite, the organic
components of bone can be degraded at a physiologic pH
with varying eﬃciencies by the type-I collagenases (Matrix
metalloproteinases- (MMPs-) 1, -8 and -13) and the gelati-
nases (MMP-2 and -9) [2, 3].
Giant cell tumor of bone (GCT) is an aggressive and
highly osteolytic bone tumor that is characterized by rapid
bone destruction. The cellular elements of GCT include both
osteoclast-like giant cells and osteoblast-like stromal cells
[4]. Previous work in our lab has shown that the stromal
cells respond to the cytokine-rich environment of the tumor
with altered expression of MMPs, predominantly with very
high levels of MMP-13 [5]. We have also shown that stromal
cell-expressed MMP-13 is, at least, partially responsible for
optimizing the bone resorption capabilities of the giant cells,
likely by recruiting them to the bone surface [6]. Finally, we
have shown that the expression of MMP-13 in the stromal
cells is regulated, in part, by the Runx2 transcription factor
[7].
The Runx2 binding site OSE2 has been found to colocal-
ize with the activator protein 1 (AP-1) transcription factor
binding site (not limited to the c-Fos and c-Jun elements)
in the promoter region of MMP-13 in human cells [8]. The
objective of this study was to use GCT stromal cells as a
model for determining the functional regulation of MMP-132 Biochemistry Research International
via AP-1 in the human bone environment in order to further
our understanding of the physiology of metalloproteinase-
induced osteolysis.
2.MaterialsandMethods
2.1. GCT Sample Collection. The use of all patient-derived
material was approved by our institution’s Research Ethics
Board, and patient informed consent was obtained indi-
vidually. The diagnosis of GCT of bone was established by
biopsy prior to surgical excision. Specimens were obtained
at the time of surgery from patients undergoing tumor
resection, and a bone pathologist veriﬁed the diagnosis of
GCT postoperatively. Tissue samples from four cases of GCT
of bone were used in this study, and all experiments were
performed in triplicate or as otherwise stated for all four
bone tumors.
2.2. Primary Cell Lines and Cultures. We established primary
cell cultures of GCT stromal tumor cells from fresh GCT
tissue. The specimens were freshly minced in Dulbecco’s
Modiﬁed Eagle Medium (D-MEM, Gibco, Burlington, ON)
producing a cell suspension with small fragments of tissue.
The resultant suspension was passed through a 20-gauge
needle prior to seeding in cell culture ﬂasks with D-
MEM supplemented with 10% fetal bovine serum (FBS),
2mM L-glutamine, 100U/mL penicillin, and 100μg/mL
streptomycin (Gibco). The cell suspension, together with
m a c e r a t e dt i s s u e ,w a sc u l t u r e di n3 7 ◦C humidiﬁed air
with 5% CO2. Culture medium was changed every two
to three days until ∼80% conﬂuence. Conﬂuent cells
(∼80%) were subcultured after dissociating with trypsin and
ethylenediaminetetraacetic acid (EDTA). Following several
successive passages, the mesenchymal stromal cells became
the predominant cell type whereas the multinucleated giant
cells were eliminated from the culture. Primary cultures
of the proliferating homogenous stromal tumor cell pop-
ulation obtained after the ﬁfth or sixth passage (without
any hematopoietic markers) and up to the tenth passage
were used for experiments. Human fetal osteoblast (hFOB)
1.19 cells (American Type Culture Collection, ATCC#CRL-
11372) were used as a control cell line. Similarly, hFOB
cells were maintained in supplemented D-MEM as described
for the GCT cells in optimized conditions. To evaluate the
eﬀects of cytokine stimulation (interleukin- (IL-) 1β) in the
recreated tumor environment as described in our previous
study [7], the same number of cells in each GCT fraction
were seeded accordingly and treated in serum-free medium
with or without 1.0ng/mL of IL-1β (R&D Systems). Cells in
all experiments in this study were induced by IL-1β.
2.3. AP-1 Protein Screening Assay. GCT stromal cells were
grown to ∼80% conﬂuence following the treatments as
described above. Cell lysates and serum-free D-MEM con-
ditioned media were collected separately following 24-
hour stromal cell culture. Additionally, the total number
of cells present at the time of the conditioned medium
collection was determined by hemocytometer. Cytoplasmic
and nuclear cellular fractionation was performed as follows:
cells were washed with cold PBS twice followed by the
addition of ice-cold cytoplasmic lysis buﬀer (10mM Tris
pH 7.6, 10mM KCl, 5mM MgCl2, 0.2% NP40, protease
inhibitor cocktail (Roche, QC, Canada), 0.5mM PMSF,
1mMDTT ,and10μg/mL leupeptin). The cells were scraped
and incubated on ice for 10min. Cellular extracts were
acquired by centrifuging the cell suspension at 3500rpm
for 5min at 4◦C. The resulting cytoplasmic supernatant was
transferred to a clean tube and the nuclear pellet was washed
with lysis buﬀer and centrifuged at 3500rpm for 5min at
4◦C. The nuclear pellet was resuspended in ice-cold nuclear
extraction buﬀer for 30–60min at 4◦C and then centrifuged
at 16000 rpm for 5min. Total protein content in the lysates
was quantiﬁed using the Bradford assay procedure (Pierce
Biotechnulogy, IL). AP-1 activity was determined using
AP-1 EZ-TFA Transcription Factor Assay (Millipore, MA)
according to manufacturer’s protocol. Brieﬂy, the nuclear
extracts in the supernatant (5μg/5μL) from each sample
were incubated in 96-well plates coated with a double-
stranded biotinylated oligonucleotide containing the ﬂanked
DNA binding consensus sequence for the AP-1 family (5 -
TGA(C/G)TCA-3 ) for 1 hour, then with speciﬁc primary
AP-1 antibody for 1 hour, and with peroxidase-conjugated
secondary antibody (1:500) for 1 hour, and subsequently
with peroxidase-conjugated secondary antibody (1:1000)
for 30min at room temperature. After the colorimetric
reaction,opticaldensitywasreadat450nm.Forcompetition
assays, cell extracts were incubated with AP-1 speciﬁc
competitor oligonucleotide (5 -TGA(C/G)TCA-3 ).
2.4. siRNA Transfection. M e s e n c h y m a ls t r o m a lc e l l so fG C T
were trypsinized and transfected with Runx2, c-Jun, and
c-Fos small interfering RNAs (siRNAs) via electropora-
tion. Stromal cells of GCT were washed and resuspended
in Opti-MEM I reduced-serum medium (Gibco). Subse-
quently, cell suspension was mixed with either 200nM
of ON-TARGETplus SMARTpool Runx2 siRNA (Thermo
Scientiﬁc-Dharmacon),Stealthc-Fosandc-JunsiRNA(Invi-
trogen), a positive Silencer siRNA control against glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH), or a
nonspecific negative control no. 1 (Ambion Inc.). Stromal
cells with siRNA mixture were electroporated using the Gene
Pulser II electroporation apparatus (Bio-Rad Laboratories)
under a single-pulse protocol with optimized combinations
of voltage and capacitance. Then, cells were plated in cell
culture ﬂasks with supplemented D-MEM. At 48 hours after
the transfection, cells were harvested for Runx2 mRNA.
Ribosomal protein S18 (RPS18) was selected among other
housekeeping genes for normalization in real-time PCR
analysis since GAPDH has been used as the positive siRNA
control. The viability of stromal cells after transfection was
evaluated by hemocytometry.
2.5. RNA Puriﬁcation and Reverse Transcription (RT). Total
RNA was isolated from GCT stromal cells using the RNeasy
Mini Kit (Qiagen, ON) as optimized in our lab. To ensure
complete removal of contaminating genomic DNA priorBiochemistry Research International 3
Table 1: Human primer sequences specially designed for real-time RT-polymerase chain reaction (PCR) ampliﬁcation.
Gene Forward/Reverse Primer sequence Accession no. Size of product (bp) Melting temperature (◦C)
c-Fos F5
  AGA ATC CGA AGG GAA AGG AA 3
 
NM 005252 150 63.6
R5
  CTT CTC CTT CAG CAG GTT GG 3
  63.8
c-Jun F5
  CAG GTG GCA CAG CTT AAA CA 3
 
NM 002228 80 63.8
R5
  GTT TGC AAC TGC TGC GTT AG 3
  63.5
MMP-13 F5
  CTT CCC AAC CGT ATT GAT GC 3
 
NM 002427 143 64.1
R5
  TTT GGA AGA CCC AGT TCA GA 3
  62.2
Runx2 F5
  TCT GGC CTT CCA CTC TCA GT 3
 
NM 004348 142 64.0
R5
  AAG GTG GCT GGA TAG TGC AT 3
  63.4
RPS18 F5
  GAT GGG CGG CGG AAA ATA G 3
 
NM 022551 165 68.4
R5
  GCG TGG ATT CTG CAT AAT GGT 3
  65.8
GAPDH F5
  CAT GAG AAG TAT GAC AAC AGC CT 3
 
NM 002046 113 62.0
R5
  AGT CCT TCC ACG ATA CCA AAG T 3
  62.5
to ﬁrst-strand synthesis, RNase-free DNase I treatment
was applied on the RNeasy column during total RNA
isolation. Single-stranded complementary DNA (cDNA) was
synthesized from 1.0μg of total RNA using the SuperScripts
III First-Strand Synthesis System for RT-PCR (Invitrogen)
and oligo(dT) 12–18 primer, following the manufacturer’s
instructions.
2.6. PCR and Real-Time PCR. The expression of GAPDH,
Runx2, MMP-13, c-Fos, and c-Jun in cells treated with vari-
ous siRNAs were analyzed using real-time RT-PCR. In brief,
real-time PCR analysis was performed on cDNA synthesized
from GCT stromal total RNA using the MiniOpticon Real-
Time PCR Detection System with the iQ SYBR Green
Supermix (Bio-Rad Laboratories, ON) according to the
manufacturer’s instructions. Cycling consisted of 40 cycles of
1 5sa t9 5 ◦C, 30s at 58◦C, and 30s at 72◦C, operated with
the Opticon Monitor software v3.1. PCR experiments were
performed in triplicate and included negative notemplate
controls. Primer pairs (Table 1) that spanned at least one
intron-exon boundary and produced amplicons in the range
of 100–200bp, were designed using the Real-time PCR
Primer Design software (VWR GenScript Corp., Piscataway,
NJ), and synthesized (Sigma-Aldrich, ON). In addition,
a primer pair for the housekeeping/reference gene RPS18
was also included. We veriﬁed the amplicon speciﬁcity and
sensitivity of all primer pairs with PCR before applying to
real-time PCR. PCR products were also separated by gel
electrophoresis using a 8% polyacrylamide gel. Bands were
visualized by UV illumination of SybrGold-stained gels and
captured using a Molecular Imager Gel Doc XR System (Bio-
Rad Laboratories). Band intensity was quantitatively ana-
lyzed by Quality One software v4.6 (Bio-Rad Laboratories).
2.7. Relative Quantiﬁcation Using Real-Time PCR. The
expression level of RPS18 was stable during siRNA treat-
ments.Therefore,RPS18wasdesignatedasthereferencegene
for relative quantiﬁcation, through which the expression of
endogenous mRNAs fromGCT stromalcellswasnormalized
with. Cycle threshold numbers (Ct) were derived from the
Figure 1: Cell morphology of homogeneous GCT stromal cells
induced by IL-1β. Representative picture was taken with light
microscope at magniﬁcation ×400.
exponential phase of PCR ampliﬁcation. Relative changes
in mRNA expression were calculated using the comparative
ΔΔCT (crossing point) method.
2.8. MMP-13 Enzyme-Linked Immunosorbent (ELISA) Activ-
ity Assays. Conditioned media were collected and concen-
trated using an Amicon Ultra-4 Centrifugal Filter Device
(Millipore, Billerica, MA). MMP-13 activity was measured
using the SensoLyte Plus 520MMP-13 Assay Kit (AnaSpec
Inc.). Concentrated conditioned media were added into
wells of a microtiter plate coated with MMP-13 speciﬁc
antibodies. After 2-hour incubation at room temperature,
APMA was added to each well to activate pro-MMP-13.
Then, with the substrate incubation, color development
from MMP-13 activity was measured using the plate reader,
with an excitation and emission wavelength of 485±20nm
and 530±25nm, respectively. Concentrated fresh media not
exposed to cells were used as a negative control.
2.9. Statistical Analysis. GraphPad Prism software (Graph-
Pad Software, Inc., USA) was used for statistical analysis.
All data are presented as mean±standard error of the mean4 Biochemistry Research International
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Figure 2: Expression of AP-1 proteins in the nucleus of GCT
stromalcells.TheAP-1screeningassayexaminestheproteinlevelof
FosB, c-Fos, Fra-1, Fra-2, JunB, JunD, and c-Jun of the AP-1 family
inthenuclearextractsofIL-1β stimulatedstromalcells.Thespeciﬁc
competitorwasusedtodeterminespeciﬁcbinding.Valuesrepresent
the means±SEM of triplicate experiments after being normalized
to the background control. ∗P<. 05 is versus corresponding
conditions with speciﬁc competitor. Statistical comparison by
analysis of variance with post hoc Tukey’s tests.
(SEM), and are representative of measurements that were
performedonfourdiﬀerentGCTpatientsamples(n = 4).To
assess variations in real-time PCR gene expression, analysis
of variance (ANOVA) and the post hoc multiple comparison
Tukey’s test (P<. 05) were applied. Measurements were
normalized to the negative control treated with nonspeciﬁc
random siRNA. Each experiment was performed at least
three times. P values <. 05 were considered to be statistically
signiﬁcant.
3. Results
3.1. Expression of AP-1 Protein in the Nucleus of GCT Stromal
Cells. To identify which members of the AP-1 family are
present in GCT stromal cells, an AP-1 screening assay was
used to detect speciﬁc transcription factor DNA binding
activity in the nuclear extracts. GCT stromal cells stimulated
with IL-1β were isolated and passaged from primary patient
tissue sample into homogeneous mesenchymal stromal cells,
as shown in Figure 1, before extracting the lysate. The AP-
1 screening assay examines both the Jun (c-Jun, JunB, and
JunD)andFos(c-Fos,FosB,Fra-1,andFra-2)familiesinAP-
1. The speciﬁc competitor double-stranded oligonucleotide
was included as an important control for verifying the
speciﬁcity of the colorimetric signal resulting from protein
binding to the labeled AP-1 probe. Only c-Fos and c-Jun
were shown to be signiﬁcantly present in GCT stromal cells
(Figure 2). Both were reduced when the speciﬁc competitor
was added to the lysate, indicating speciﬁc binding.
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Figure 3: Relative mRNA expression of the Runx2 and AP-1
transcription factors based on real-time RT-PCR. The expression
of c-Jun, c-Fos, and Runx2 in GCT stromal cells treated with
cytokines IL-1β for 24h in serum-free media was analyzed using
real-time PCR. The ΔΔCT method was used to calculate the real-
time RT-PCR fold change using RPS18 mRNA for normalization,
and all changes in expression are relative to the control without any
treatment. Triplicate independent real-time PCR were performed.
3.2. MMP-13 Expression with AP-1 and Runx2 Knockdown.
Tore-conﬁrmthepresenceandexpressionofc-Fosandc-Jun
of AP-1 in GCT stromal cells, the baseline mRNA expression
level of c-Fos, c-Jun, and Runx2 was determined using real-
timePCR.ThemRNAexpressionofthesethreetranscription
factors was relatively low into the hundredth level relative to
RPS18 expression (Figure 3). c-Fos had a similar expression
level to that of Runx2, but c-Jun exhibited a 5-6-fold higher
expression level.
Next, to further elucidate the role of AP-1 and Runx2
in MMP-13 transcriptional regulation, we depleted var-
ious combinations of c-Fos, c-Jun, and Runx2 in the
mesenchymal stromal cells of GCT by using RNA inter-
ference. Random siRNA served as the negative control.
All siRNA treatments (c-Fos, c-Jun, Runx2, and c-Fos+c-
Jun, c-Fos+c-Jun+Runx2) were normalized to the random
siRNA negative control. The expression of c-Jun was 40–
60% suppressed when treated with c-Jun, and c-Fos+c-
Jun,c-Fos+c-Jun+Runx2siRNA,respectively(Figure 4(a)).
More than 70% of Runx2 expression was depleted in
both Runx2 and c-Fos+c-Jun+Runx2 siRNA conditions,
as detected by real-time PCR (Figure 4(b)). Importantly,
MMP-13 expression was decreased by 40–50% following
knockdown of c-Jun alone, Runx2 alone, c-Fos and c-Jun in
combination, and c-Fos, c-Jun and Runx2 in combination
(Figure 4(c)). Yet, the lack of eﬀect in MMP-13 suppression
may be due to the low eﬃciency of the cFos knockdown. As a
test of transfection eﬃciency, GAPDH mRNA was decreased
by70%whentreatedwiththeGAPDHsiRNA butunaﬀected
in the random and other siRNA conditions (Figure 4(d)).
3.3. MMP-13 Activity with AP-1 and Runx2 Knockdown.
To validate the eﬀect of silencing c-Fos, c-Jun, and Runx2
on their downstream target MMP-13 at the translational
level, MMP-13 enzyme activity was measured from cultureBiochemistry Research International 5
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Figure 4: The eﬀect of siRNA knockdown on c-Fos, c-Jun, Runx2, MMP-13, and GAPDH mRNA expression in the IL-1β -induced
mesenchymal stromal cells of GCT. GCT stromal cells were transfected by electroporation with corresponding siRNA for 48h. Treated
samples were examined using real-time PCR. The ΔΔCT method was used to calculate the real-time RT-PCR fold change using RPS18
mRNA as an endogenous control. Three independent experiments were performed. mRNA expression of (a) c-Jun, (b) Runx2, (c) MMP-13,
and (d) GAPDH upon treatment with combinations of siRNA. ∗P<. 05 is versus random nonspeciﬁc siRNA control. Statistical comparison
by analysis of variance with post hoc Tukey’s tests.
medium collected from the siRNA treatments. The per-
centage of MMP-13 activity (Figure 5) exhibited a similar
trend to measurements from the MMP-13 real-time PCR
data (Figure 4(c)). However, c-Fos siRNA demonstrated a
30% knockdown of MMP-13 activity as shown in Figure 5,
as compared to its insigniﬁcant eﬀe c to nM M P - 1 3t r a n -
scription. c-Jun and Runx2 gene silencing resulted in 40%
and 55% knockdown in MMP-13 activity, respectively.
Interestingly, AP-1 knockdown resulted in greater MMP-13
activitysilencingthandidRunx2knockdown,indicatingthat
both transcription factors play a role in MMP-13 expression
and activity in these cells.
4. Discussion
The regulation of MMPs plays an important role in tis-
sue remodeling associated with various physiological and
pathological processes involving turnover of the extracellular
matrix. MMP-13 has a key role in the MMP activation
cascade and appears to be critical in bone metabolism,
homeostasis,osteoarthritis,andrheumatoidarthritis[9],but
is also highly associated with tumor invasion and metastasis
[10]. A high level of MMP-13 expression is the unique
gene proﬁle signature of the stromal cells of GCT compared
to other tissues and cell lines [5]. The surge of MMP-13
expression in GCT stromal cells is induced by cytokines
secreted by the multinucleated giant cells in the tumor
environment [7].
Intervention aﬀecting the regulation of MMPs in patho-
logic tissues has substantial clinical potential. At least
56MMP inhibitors have been assessed as candidates in
various therapeutic areas, mainly for targeting cancer, arthri-
tis, or cardiovascular diseases [11]. Due to unacceptable
side eﬀect proﬁles, direct MMP inhibitors have failed in6 Biochemistry Research International
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activity in IL-1β-stimulated GCT cells. Filtered and concentrated
conditioned media from siRNA silenced GCT stromal cells were
analyzed using the MMP-13 activity kit as per optimization in our
lab. Results of the ELISA activity assay are shown in triplicate with
error bars. The MMP-13 activity levels were normalized to the
amount of total protein for each condition.
many clinical trials [12, 13]. Thus, other targeted treatment
alternatives are needed, such as aiming at a higher level of
regulation of MMP-13 by transcription factors.
To get a broader scope of how transcription factors
regulate the cytokine-stimulated MMP-13 expression in
GCT stromal cells, we speciﬁcally examined AP-1 in this
study to extend our understanding of Runx2 as a modulator
of MMP-13. Both Runx2 and AP-1 have binding sites in the
promoter region of MMP-13. Selvamurugan et al. reported
that activation of the MMP-13 promoter requires both the
AP-1 and Runx2 sites in vitro and in vivo conditions in mice
[14], as well as in cultured osteosarcoma cell lines [15].
AP-1 is a transcription factor, which is a heterodimeric
protein, composed of proteins belonging to the c-Fos, c-
Jun, ATF, and JDP families. It regulates gene expression
in response to a variety of stimuli, including cytokines,
growthfactors,stress,bacterial,andviralinfections[16].AP-
1 in turn controls a number of cellular processes including
diﬀerentiation, proliferation, and apoptosis [17]. Since AP-1
consists of multiple protein families, two central members,
c-Fos and c-Jun, were identiﬁed as highly expressed in GCT
stromal cells using both the AP-1 family screening assay and
real-time PCR.
The results of siRNA knockdown in GCT cells showed
that silencing c-Jun and Runx2 signiﬁcantly silenced the
expression of MMP-13. However, knocking down all three
transcription factors in the c-Fos+c-Jun+Runx2 siRNA
condition did not reduce the MMP-13 expression further,
indicating a baseline endogenous expression level of MMP-
13 controlled by other factors or pathways. This result also
suggests that no synergistic interaction happened between
the AP-1 and Runx2 transcription factors in MMP-13 reg-
ulation. We found the c-Jun element of AP-1 to show higher
expression and greater control over MMP-13 expression in
GCT stromal cells that the c-Fos element of AP-1. Both
c-Fos and c-Jun are end targets of the ERK and JNK
pathways such that inhibiting either pathway in our previous
study demonstrated a similar trend in subduing MMP-13
expression [7]. Therefore, upstream signaling may play a
key role in recruiting the elements of AP-1 in MMP-13
regulation.
From the results of this study, it is clear that the
functionalregulationofMMP-13requiresboththeAP-1and
Runx2 transcription factors in our GCT stromal cell model.
Complex regulatory loops exist in the cells of the skeletal
system, which spatially and temporally control the progres-
sion of bone and cartilage cell maturation and coordinate
it with events in surrounding tissues [18]. Transcription
factors are downstream in the signaling cascade where cells
are exposed to extracellular or intercellular signals. What
controls these transcription factors could be the ultimate
target for clinical intervention in bone pathology. For
example, it has been shown that parathyroid hormone-
related peptide (PTHrP) delays chondrocyte diﬀerentiation
by suppressing Runx2 through a feedback regulatory loop
in which Indian hedgehog (Ihh) induces PTHrP expression,
while PTHrP in turn downregulates Ihh [19–21]. Hence,
examining the relationship between PTHrP, Ihh, Runx2, and
MMP-13 in the bone microenvironment and tumorigenesis
in GCT would be an interesting followup to the current
study.
In summary, we have demonstrated that c-Fos and c-
Jun of the AP-1 family are expressed by GCT stromal cells.
The cytokine-induced MMP-13 expression in these cells is
strongly suppressed by various combinations of c-Fos, c-Jun,
and Runx2 gene knockdown. Our results indicate that c-
Fos, c-Jun, and Runx2 all regulate MMP-13 expression and
activity to a certain degree in GCT mesenchymal stromal
cells. We propose that cytokines secreted by multinucleated
giantcellsstimulateMMP-13productionintheGCTstromal
cells through both AP-1 and Runx2 transcription factors.
The regulation of these transcription factors may therefore
serve as targets in treatment strategies for this destructive
tumorandotherdegenerativediseasesofthemusculoskeletal
system where MMP-13 is the most prominently implicated
protease. Nevertheless, more evidence is needed to clarify
what upstream extracellular or intercellular signals modulate
AP-1 and Runx2 in controlling MMP-13 regulation in the
human bone environment in order to further our under-
standing of the physiology of metalloproteinase-induced
osteolysis.
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